Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lisata Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LSTA
Nasdaq
8731
https://www.lisata.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lisata Therapeutics Inc
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
- Apr 10th, 2024 1:53 pm
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Apr 9th, 2024 12:30 pm
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
- Apr 3rd, 2024 12:30 pm
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
- Mar 22nd, 2024 4:25 pm
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Mar 21st, 2024 12:00 pm
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
- Mar 15th, 2024 11:37 am
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
- Mar 8th, 2024 1:35 pm
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
- Mar 5th, 2024 1:35 pm
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
- Mar 4th, 2024 1:00 pm
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript
- Mar 2nd, 2024 1:29 pm
Q4 2023 Lisata Therapeutics Inc Earnings Call
- Mar 1st, 2024 1:29 pm
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Feb 29th, 2024 9:05 pm
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
- Feb 22nd, 2024 1:00 pm
Lisata Therapeutics to Present at BIO CEO & Investor Conference
- Feb 20th, 2024 1:00 pm
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
- Jan 23rd, 2024 5:12 pm
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
- Jan 18th, 2024 1:30 pm
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
- Jan 17th, 2024 1:00 pm
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
- Jan 4th, 2024 1:00 pm
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
- Dec 12th, 2023 1:00 pm
Lisata Therapeutics to Present at NobleCon19 Investor Conference
- Nov 28th, 2023 9:05 pm
Scroll